Localized Affinity-Based Delivery of Prinomastat for Cancer Treatment.

Glioblastoma multiforme patients suffer a median survival of 14 months, facilitated by the highly invasive nature of this cancer that allows for it to evade conventional therapy. Prinomastat targets the essential matrix metalloproteinase degradation of the extracellular matrix needed for cancer invasion; however, its clinical potential is impeded by adverse musculoskeletal side effects. By localizing delivery of prinomastat via cyclodextrin polymers, systemic side effects can be bypassed. In this letter, we demonstrate that prinomastat delivery from β-cyclodextrin polymers results in months-long inhibition of MMPs as measured by gelatin zymography, more appropriately addressing the time frame of cancer cell invasion.